Slide 1: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation may contain forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs
Slide 2: Business Lines (Breadth) and Growth Area Focus (Depth)
------------------------------------------------- Business Lines (Breadth) ------------------------------------------------- Cardiovascular & Metabolism ------------------------------------------------- Cancer Diagnostics ------------------------------------------------- Neurology ------------------
Slide 3: Value Creation from the Integration of Lab Testing and Clinical Information
Value Creation from the Integration of Lab Testing and Clinical Information Integration of Health Information / Value / Investment Phase 1 Individual tests Phase 2 Integration of ordering and results for lab testing Phase 3 Integration of non-lab testing into ordering and results Phase 4 Insight dri
Slide 4: Providing Holistic Solutions Centered on Guideline Supported Standards of Care
Providing Holistic Solutions Centered on Guideline Supported Standards of Care ENABLERS Providers Payers Patients Easy to use testing panels defined by professional guidelines Lab ordering, rules and alerts - decision support Integration of imaging results included in guidelines testing Enhanced and
Slide 5: Value from Combining Routine, Guideline Mandated Testing with Esoteric Solutions
Value from Combining Routine, Guideline Mandated Testing with Esoteric Solutions Guidelines Supported Testing Routine Often Primary Care Dementia Dementia Testing - PCP Hepatitis C HCV screening and routine workup Metabolic and Cardiac Disease Metabolic syndrome, diabetes and cardiovascular risk tes
Slide 6: Examples of Combining Routine and Esoteric Testing
Examples of Combining Routine and Esoteric Testing Guidelines Supported Screening (PCP) Dementia Dementia Testing - PCP 25 million people in U.S. Hepatitis C HCV screening and routine workup 78 million people in U.S. Metabolic and Cardiac Disease Metabolic syndrome, diabetes and cardiovascular risk
Slide 7: Advanced Diagnostic Technology and Expertise Enables our Esoteric Growth Programs
Advanced Diagnostic Technology and Expertise Enables our Esoteric Growth Programs Mass Spectrometry: LCMSMS, Other Largest LCMSMS Lab with many important firsts Point of Care Simplexa PCR Influenza FDA approved Other ASR content available Advanced Sequencing 1st Application Released 2012 DNA Combing
Slide 8: Key Takeaways - Grow Esoteric Through Disease Focus
Key Takeaways - Grow Esoteric Through Disease Focus o Focus on delivering holistic solutions responsive to the needs of clinicians and payors - aligned with commercial objectives o We will address a significant near term clinical opportunity to close the "guidelines gap" in care o Investments in tec
Slide 9: Key Takeaways — Grow Esoteric Through Disease Focus
Key Takeaways — Grow Esoteric Through Disease Focus * Focus on delivering holistic solutions responsive to the needs of clinicians and payors — aligned with commercial objectives * We will address a significant near term clinical opportunity to close the “guidelines gap” in care * Investments in tec